307
Participants
Start Date
October 28, 2022
Primary Completion Date
May 28, 2025
Study Completion Date
May 28, 2025
Ofatumumab
There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hanover
Novartis Investigative Site, Minden
Novartis Investigative Site, Marburg
Novartis Investigative Site, Gladenbach
Novartis Investigative Site, Giessen
Novartis Investigative Site, Düsseldorf
Novartis Investigative Site, Düsseldorf
Novartis Investigative Site, Remscheid
Novartis Investigative Site, Bochum
Novartis Investigative Site, Essen
Novartis Investigative Site, Essen
Novartis Investigative Site, Gelsenkirchen
Novartis Investigative Site, Osnabrück
Novartis Investigative Site, Quakenbrück
Novartis Investigative Site, Cologne
Novartis Investigative Site, Bonn
Novartis Investigative Site, Alzey
Novartis Investigative Site, Siegen
Novartis Investigative Site, Hagen
Novartis Investigative Site, Frankfurt am Main
Novartis Investigative Site, Bad Homburg
Novartis Investigative Site, Mannheim
Novartis Investigative Site, Kaiserslautern
Novartis Investigative Site, Stuttgart
Novartis Investigative Site, Stuttgart
Novartis Investigative Site, Böblingen
Novartis Investigative Site, Sinsheim
Novartis Investigative Site, Pforzheim
Novartis Investigative Site, Rülzheim
Novartis Investigative Site, Unterhaching
Novartis Investigative Site, Bogen
Novartis Investigative Site, Bayreuth
Novartis Investigative Site, Bamberg
Novartis Investigative Site, Altenburg
Novartis Investigative Site, Chemnitz
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY